Competitive inhibition of IDO with 1-methyl-d-tryptophan (1-MT) has been widely used in preclinical studies, and has been shown to suppress progression of IDO-expressing ovarian cancer cells in a syngeneic mouse model [90]. The gene discussed is IDO1; the disease is ovarian cancer.